Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
GALAPAGOS SEPTEMBER 2018
Volgen
BLOO7 schreef op 18 september 2018 10:27 :
[...]
Jos, we staan op dezelfde lijn.
als jij nou keurig op de lijn blijft staan dan ga ik lekker languit op de bank hangen, goed?
beetje spiegelkoers van gisteren straks steil naar boven?
Ik neem aan dat dat positief nieuws is ?pbs.twimg.com/media/DnUv3cUXoAAZmnC.j...
Staat er ook een datum bij?
@Tuut : Bericht van vandaag.
JayR schreef op 18 september 2018 10:22 :
De forumleden die de koers al naar €90 zagen gaan zijn vandaag even wat anders doen en komen weer terug als we op -2% staan vandaag.
gefrustreerde stemmingmakers zijn dat....
egeltjemetstekel schreef op 18 september 2018 11:19 :
[...] als jij nou keurig op de lijn blijft staan dan ga ik lekker languit op de bank hangen, goed?
Ik heb geen tijd om te bankhangen... Ik heb mijn positie nog iets uitgebreid. Laat maar komen dat...
Galop schreef op 18 september 2018 11:18 :
[...]
Heb jij een link dat AQR aandelen heeft van Gilead of ga je daar maar vanuit.
www.nasdaq.com/symbol/gild/institutio...
BLOO7 schreef op 18 september 2018 12:06 :
[...]
Ik heb geen tijd om te bankhangen...
Ik heb mijn positie nog iets uitgebreid.
Laat maar komen dat...
tsja maar om dan je tijd te gaan verdoen met op een lijn staan...
finance.yahoo.com/news/galapagos-nv-b... Nog niet geplaatst volgens mij. “A safety profile completely free of deadly blood clots through the first of three phase 3 RA studies suggests AbbVie let go of the wrong tablet. The FDA couldn't get over a handful of similar issues that appeared during RA studies with another drug in the same class, Eli Lilly's Olumiant, and severely limited its approval. If it is approved, healthcare providers aren't going to forget that AbbVie's upadacitinib has been associated with cases of pulmonary embolism either.”
egeltjemetstekel schreef op 18 september 2018 12:32 :
[...] tsja maar om dan je tijd te gaan verdoen met op een lijn staan...
Dat kost geen tijd egeltje. Misschien vatten egeltjes dat niet?
Als we een paar dagen tegen de 100 gaan tikken wordt het vanzelf een nieuwe steun :)
BLOO7 schreef op 18 september 2018 12:46 :
[...]
Dat kost geen tijd egeltje.
Misschien vatten egeltjes dat niet?
klokje tikt even hard of je nou op jouw lijn staat of op mijn bank ligt. Of is 't soms een magische stippellijn waar heel andere regels voor gelden? Dan is E zeker ook geeneens MCkwadraat meer?
Galapagos, koopwaardig, vooral voor mensen die wat risico durven nemen: Filgotinib is on fire Three years ago, AbbVie dumped Galapagos NV's filgotinib for another JAK inhibitor that looked a lot prettier at the time. AbbVie's upadacitinib appeared as effective if not better in mid-stage testing, and it was much farther along on the clinical development timeline. To top it off, AbbVie won't have to share revenue with Galapagos if upadacitinib's upcoming application for the treatment of rheumatoid arthritis (RA) earns FDA approval. Unburdened by a robust pipeline of its own, Gilead Sciences (NASDAQ: GILD) was eager to give Galapagos $300 million in cash and a $425 million equity investment for rights to filgotinib after AbbVie walked away. If the treatment earns approvals, Galapagos is also eligible to receive tiered royalties of 20% and higher from Gilead. AbbVie's leading RA injection, Humira, is on pace to achieve $20 billion in sales this year, even though it just isn't an option for many RA patients. As an easy-to-swallow alternative to Humira, filgotinib has a shot at becoming a megablockbuster too, especially if a best-in-class safety profile helps it stand out among its peers. A safety profile completely free of deadly blood clots through the first of three phase 3 RA studies suggests AbbVie let go of the wrong tablet. The FDA couldn't get over a handful of similar issues that appeared during RA studies with another drug in the same class, Eli Lilly 's Olumiant, and severely limited its approval. If it is approved, healthcare providers aren't going to forget that AbbVie's upadacitinib has been associated with cases of pulmonary embolism either. If filgotinib can make it through a commercial launch with a safety profile unsullied by deadly blood clots and expand to groups beyond RA, Gilead and Galapagos could turn the drug into a $6 billion-per-year cash cow at its peak. That encouraging peak sales estimate includes potential expansions to indications beyond RA. Filgotinib recently aced a mid-stage trial with ankylosing spondylitis patients, and it's in late-stage development for Crohn's disease and ulcerative colitis. A doctor with cash in lab coat pocket. Image source: Getty Images. Beyond filgotinib The lead program gets so much attention that it's easy to overlook a slew of additional clinical-stage candidates aimed at four separate diseases and the huge pile of cash Galapagos has to develop them. The company finished June with $1.2 billion cash, cash equivalents, and securities and recently raised another $300 million in a secondary share offering. Right now, it looks as if Galapagos has enough to develop three clinical-stage candidates aimed at idiopathic pulmonary fibrosis (IPF), a progressive stiffening of lung tissue that threatens the lives of around 200,000 people in the U.S. and EU that lacks treatment options. The company's most advanced IPF candidate is ready to begin a phase 3 study. Before the year's out, the company also expects an interim readout from a triple combination therapy for the treatment of cystic fibrosis (CF). Vertex Pharmaceuticals (NASDAQ: VRTX) will probably record $3.0 billion in sales to CF patients this year, largely because it has the only treatments available at the moment. We'll know if Galapagos' triple combo will have a chance at breaking into the space dominated by Vertex when the phase 2 Falcon study reads out sometime in the near future. Reasons to be nervous Galapagos' recent enterprise value of $4.8 billion is awfully high for a drugmaker that doesn't have any drugs for sale yet. Investors are expecting blockbuster sales for filgotinib that will never come if its safety profile takes a hit, and the program still has opportunities to stumble. Although filgotinib sailed through Finch 2 without any issues, it was a 24-week trial with 423 patients. The ongoing Finch 1 and Finch 3 studies are designed for 52 weeks and enrolled a combined 2,850 patients. If a few people in the groups receiving filgotinib end up hospitalized for dangerous blood clots, for any reason, investors could suffer some swift losses. A buy now? Having deep-pocketed partners to pick up the tab for phase 3 development of partnered candidates means Galapagos can head toward commercialization at full speed without depleting its enormous cash pile. This would give the company's burgeoning pipeline of mid- to late-stage programs a chance to resuscitate Galapagos' stock price if the filgotinib program chokes before it reaches the finish line. Galapagos is a buy, but only for investors at the high end of the risk-tolerance spectrum. Everyone else should consider adding this clinical-stage biotech stock to their watchlist right now. 10 stocks we like better than Galapagos When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Galapagos wasn't one of them! That's right -- they think these 10 stocks are even better buys. Click here to learn about these picks! *Stock Advisor returns as of August 6, 2018 Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This article appears in: Personal Finance , Stocks Referenced Symbols: RA , CF , GLPG , LLY , GILD
leden van de state generaal, ik smeek u een leuke beurs vanmiddag. Morgen, oke tomas, doei.......) (.................... Farmaceuten ontduiken belastingen, hee slecht nieuws.
plukkezot, ze moeten er ook zijn...
egeltjemetstekel schreef op 18 september 2018 12:53 :
[...] klokje tikt even hard of je nou op jouw lijn staat of op mijn bank ligt. Of is 't soms een magische stippellijn waar heel andere regels voor gelden? Dan is E zeker ook geeneens MCkwadraat meer?
Ik heb zo mijn eigen regels... als het maar geld in het laadje brengt. Met het schitterende bedrijf Galapagos bezitten we in ons België een pareltje van goudwaarde. Ik verwacht een bod van Gilead, omdat het moet van hun kant.
Dit is voorlopig het enige hangijzer nog: Although filgotinib sailed through Finch 2 without any issues, it was a 24-week trial with 423 patients. The ongoing Finch 1 and Finch 3 studies are designed for 52 weeks and enrolled a combined 2,850 patients. If a few people in the groups receiving filgotinib end up hospitalized for dangerous blood clots, for any reason, investors could suffer some swift losses.
Zitten de nieuwe aandelen al in de koers verwerkt nu? Of hoe/wanneer gebeurt dat?
JayR schreef op 18 september 2018 10:32 :
Ik blijf wel nieuwsgierig naar de strategie van AQR
Die bouwen niet af ,ja misschien af en toe met een paar tienden van %ten,ze spelen samen met Gilead,als dat geen belangen verstrengeling is dan snap ik het ook niet. Daar word niet naar gekeken door AFM.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)